Exos Asset Management’s Pfizer PFE Stock Holding History

Exos Asset Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,137	Closed	-$84K	–	635
2021 Q2	$84K	Buy	+2,137	New	+$83.1K	0.04%	413

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Exos Asset Management's PFE Position: Q3 2021 in Review

Exos Asset Management sold out of Pfizer (PFE) in Q3 2021, closing a stake of 2,137 shares — an estimated $84K sold.

Exos Asset Management first reported a position in PFE in Q2 2021 and held it in 1 quarter. The position peaked at $84K in Q2 2021. 2,804 funds tracked by Wall St. Rank hold PFE as of Q3 2021.

Exos Asset Management reported no remaining Pfizer position as of Q3 2021 after selling out during the quarter.
Exos Asset Management sold 2,137 Pfizer shares in Q3 2021, an estimated $84K.
Exos Asset Management first reported a position in Pfizer in Q2 2021 and held it in 1 quarter.
Exos Asset Management's Pfizer position peaked at $84K in Q2 2021.
2,804 funds tracked by Wall St. Rank held Pfizer as of Q3 2021.

Based on Exos Asset Management's 13F filing for Q3 2021, filed 25 Oct 2021.